Hepatitis B Virus (HBV) Therapeutics : US Drug Forecast and Market Analysis to 2024
©
Research Beam added a report on “Hepatitis B Virus (HBV) Therapeutics - US Drug Forecast and Market Analysis to 2024”
Summary
ResearchBeam Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.
Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.
The main driver of the US market over the forecast period will be the launch of novel therapies: most notably, the three adjunct therapies. These agents are aimed to be used alongside marketed oral NAs, and to improve the immunological cure rate, which is measured by the clearance or seroconversion of HBsAg and sustained HBV DNA suppression.
Get Sample of Report Here: http://www.researchbeam.com/hepatitis-b-virus-hbv-therapeutics-us-drug-forecast-and-analysis-to-2024-market
Scope
- Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US HBV market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HBV.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
Table of Contents
1 Table of Contents
2 Introduction
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
4 Disease Management
4.1 Diagnosis and Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
8 Market Outlook
8.1 US
9 Appendix
Enquire Here: http://www.researchbeam.com/hepatitis-b-virus-hbv-therapeutics-us-drug-forecast-and-analysis-to-2024-market/enquire-about-report
About Us:
With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.
With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
Contact Us:
James Jordan
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax : +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com
Summary
ResearchBeam Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.
Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.
The main driver of the US market over the forecast period will be the launch of novel therapies: most notably, the three adjunct therapies. These agents are aimed to be used alongside marketed oral NAs, and to improve the immunological cure rate, which is measured by the clearance or seroconversion of HBsAg and sustained HBV DNA suppression.
Get Sample of Report Here: http://www.researchbeam.com/hepatitis-b-virus-hbv-therapeutics-us-drug-forecast-and-analysis-to-2024-market
Scope
- Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US HBV market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HBV.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
Table of Contents
1 Table of Contents
2 Introduction
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
4 Disease Management
4.1 Diagnosis and Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
8 Market Outlook
8.1 US
9 Appendix
Enquire Here: http://www.researchbeam.com/hepatitis-b-virus-hbv-therapeutics-us-drug-forecast-and-analysis-to-2024-market/enquire-about-report
About Us:
With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.
With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
Contact Us:
James Jordan
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax : +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com